PDCD1 and hereditary clear cell renal cell carcinoma: Another combination is pembrolizumab (PD-1 inhibitor) and axitinib (VEGF-vascular endothelial growth factor inhibitor), used for renal cell carcinoma, leveraging the anti-angiogenic effects of axitinib to enhance anti-tumor immune response.